{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:22:59Z","timestamp":1766269379003,"version":"build-2065373602"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are widely used in the treatment of various cancers, but they may lead to multi-system immune-related adverse events (irAEs). Subacute cutaneous lupus erythematosus (SCLE) has rarely been reported, however, it can cause severe adverse cutaneous reactions, which then affect patients\u2019 anti-tumor treatment decisions as well as life and survival. This study presented the first case report of SCLE caused by nivolumab in the patient with sigmoid colon cancer, and summarized the clinical manifestations, diagnostic criteria and specific treatment plans of this type of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>After the treatment of sigmoid colon cancer with nivolumab, a 72-year-old male patient developed multiple well-demarcated erythematous annular plaques on the upper trunk and dorsal forearm, with erythematous borders and central clearing. The infiltrating erythema was observed behind the ear and in the occipital area on both sides, with thin scales attached and gradually increasing. Serum laboratory testing indicated an elevated anti-nuclear antibody (ANA) titer, strong positive for Sjogren\u2019s syndrome-A (SS-A)\/Ro and Sjogren\u2019s syndrome-B (SS-B) antibodies. The pathological result of skin biopsy suggested SCLE. In terms of treatment, the patient\u2019s rash was significantly improved after suspending the treatment of nivolumab and adding methylprednisolone and hydroxychloroquine. At present, the patient survived and the rash was stable after seventeen months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Through the discussion of this case, the typical characteristics, diagnostic criteria and treatment of DI-SCLE caused by ICIs are summarized in detail, which provides help for early clinical diagnosis and effective management of DI-SCLE caused by ICIs, and effective treatment is expected to prolong the survival period and improve the quality of life of the patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1674823","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:22:28Z","timestamp":1762147348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-induced subacute cutaneous lupus erythematosus in a patient with sigmoid colon cancer: a case report and review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Li","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000536","article-title":"Subacute\u00a0cutaneous lupus erythematosus induced by nivolumab: two case reports\u00a0and a literature review","volume":"29","author":"Zitouni","year":"2019","journal-title":"Melanoma Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"Itc17","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann Internal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1138493","article-title":"Immunotherapies for advanced hepatocellular carcinoma","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol"},{"key":"B7","article-title":"Drug-induced lupus erythematosus","volume-title":"StatPearls","author":"Solhjoo","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs","volume":"148","author":"Bataille","year":"2021","journal-title":"Annales dermatologie venereologie"},{"key":"B9","article-title":"Subacute cutaneous lupus erythematosus","volume-title":"StatPearls","author":"Jatwani","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2390644","article-title":"Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus","volume":"24","author":"He","year":"2025","journal-title":"Expert Opin Drug safety"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1324231","article-title":"Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report","volume":"14","author":"Fietz","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1334718","article-title":"Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature","volume":"11","author":"Khorasanchi","year":"2024","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00320-5","article-title":"Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus","volume":"20","author":"Bolton","year":"2020","journal-title":"Drugs R&D"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241245078","article-title":"Drug-induced lupus erythematosus in childhood: Case-based review","volume":"33","author":"Kaya Akca","year":"2024","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2022.07.007","article-title":"Subacute cutaneous lupus erythematosus: A facultative paraneoplastic dermatosis","volume":"40","author":"Lazar","year":"2022","journal-title":"Clinics Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergology international: Off J Japanese Soc Allergology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"23136","DOI":"10.1038\/s41598-024-72118-3","article-title":"Preclinical comparison of prolgolimab, pembrolizumab and nivolumab","volume":"14","author":"Gordeev","year":"2024","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade6256","article-title":"Transmembrane domain-driven PD-1 dimers mediate T cell inhibition","volume":"9","author":"Philips","year":"2024","journal-title":"Sci Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.23736\/s1824-4785.21.03395-1","article-title":"Prognostic importance of SUVmax values evaluated by 18F-FDG-PET\/CT before nivolumab treatment in patients with metastatic renal cell carcinoma","volume":"67","author":"Gulturk","year":"2023","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/acr-22-87","article-title":"Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report","volume":"7","author":"Potluri","year":"2023","journal-title":"AME Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1801753","article-title":"Liquid biopsy and colorectal cancer","volume":"13","author":"Aggarwal","year":"2024","journal-title":"South Asian J cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4472","article-title":"Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic","volume":"91","author":"Phillips","year":"2004","journal-title":"Br J surgery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)65436-3","article-title":"High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability","volume":"154","author":"Dolcetti","year":"1999","journal-title":"Am J pathology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.Cd-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.07.002","article-title":"Tumor-agnostic drug development in dMMR\/MSI-H solid tumors","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12681","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab","volume":"59","author":"Liu","year":"2018","journal-title":"Australas J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000523800","article-title":"Nivolumab-Induced de novo Discoid Lupus Erythematosus","volume":"14","author":"Manjunath","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal transduction targeted Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221104237","article-title":"Proton pump inhibitor induced subacute cutaneous lupus erythematosus: Clinical characteristics and outcomes","volume":"31","author":"Poh","year":"2022","journal-title":"Lupus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/his.14440","article-title":"Cutaneous manifestations of lupus erythematosus: a practical clinicopathological review for pathologists","volume":"80","author":"Bitar","year":"2022","journal-title":"Histopathology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000522","article-title":"Drug-induced lupus erythematosus: an update on drugs and mechanisms","volume":"30","author":"He","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/jcm12030987","article-title":"Current knowledge of the molecular pathogenesis of cutaneous lupus erythematosus","volume":"12","author":"Miyagawa","year":"2023","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320983448","article-title":"Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer","volume":"30","author":"Gambichler","year":"2021","journal-title":"Lupus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10110.x","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00403-024-03484-1","article-title":"Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1\/PD-L1 inhibitors","volume":"316","author":"Wu","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis rheumatism"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5070\/D32510045821","article-title":"Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-015-0706-2","article-title":"Pathophysiology of cutaneous lupus erythematosus","volume":"17","author":"Achtman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J cutaneous pathology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2013.10393","article-title":"Cutaneous lupus erythematosus","volume":"150","author":"Eastham","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann New York Acad Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jdcr.2021.06.030","article-title":"A case of paraneoplastic subacute cutaneous lupus erythematosus in a patient with metastatic melanoma","volume":"15","author":"D\u2019Gama","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/806835","article-title":"Unusual paraneoplastic presentation of cholangiocarcinoma","volume":"2015","author":"Opneja","year":"2015","journal-title":"Case Rep Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00403-008-0895-5","article-title":"Drug-induced lupus erythematosus","volume":"301","author":"Vedove","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1986.01660190043013","article-title":"Cutaneous paraneoplastic syndromes","volume":"122","author":"McLean","year":"1986","journal-title":"Arch Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2011.02.015","article-title":"Subacute cutaneous lupus erythematosus and cancer: two cases and literature review","volume":"138","author":"Gantzer","year":"2011","journal-title":"Annales dermatologie venereologie"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10397.x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart","volume":"165","author":"Marzano","year":"2011","journal-title":"Br J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/dad.0000000000001119","article-title":"Photosensitive eruption in a patient with metastatic non-small cell lung cancer: challenge","volume":"41","author":"Knapp","year":"2019","journal-title":"Am J dermatopathology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/dad.0000000000001120","article-title":"Photosensitive eruption in a patient with metastatic non-small cell lung cancer: answer","volume":"41","author":"Knapp","year":"2019","journal-title":"Am J dermatopathology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13538","article-title":"Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review","volume":"62","author":"Diago","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B59","unstructured":"2017"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2213887","article-title":"Efficacy and safety of compound glycyrrhizin in the patients with vitiligo: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2299597","article-title":"A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria","volume":"35","author":"Chen","year":"2024","journal-title":"J Dermatol Treat"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1254605","article-title":"Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Yu","year":"2017","journal-title":"Curr Med Res opinion"},{"key":"B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/2229-5178.126020","article-title":"Cutaneous lupus erythematosus: An update","volume":"5","author":"Gr\u00f6nhagen","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e941835","DOI":"10.12659\/ajcr.941835","article-title":"Nivolumab-induced cytokine release syndrome: A case report and literature review","volume":"25","author":"Ntwali","year":"2024","journal-title":"Am J Case Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2001.00491.x","article-title":"Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma","volume":"42","author":"Ho","year":"2001","journal-title":"Australas J Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1674823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:22:33Z","timestamp":1762147353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1674823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":66,"alternative-id":["10.3389\/fonc.2025.1674823"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1674823","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1674823"}}